Neuregulin 1 (Nrg1) has been widely recognized as a candidate gene for schizophrenia. This study therefore investigated mice heterozygous for a mutation in the transmembrane domain of this trophic factor (Nrg1 +/x mice) in a number of behavioural test systems with relevance to schizophrenia, including psychotropic drug-induced locomotor hyperactivity and prepulse inhibition (PPI) of startle. Baseline locomotor activity in the open field or in photocell cages was slightly, but significantly enhanced in Nrg1 +/x mice compared to wild-type littermate controls at age 12-16 wk, but not at age 6 months. The ability of amphetamine, phencyclidine (PCP) or MK-801 to induce locomotor hyperactivity was not significantly different between the genotypes. There was no difference in baseline PPI, startle or startle habituation and there was no difference in the effect of apomorphine, amphetamine or MK-801 on any of these parameters. Only treatment with the 5-HT 1A receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) showed a differential effect between genotypes, with a disruption of PPI occurring in Nrg1 +/x mice compared to no effect in wild-type controls. This treatment also induced a significant reduction of startle which could have influenced the result. The density of dopamine D 2 receptors in the forebrain and of 5-HT 1A receptors in the hippocampus and raphe nuclei was not different between Nrg1 +/x mice and controls. These studies add to the knowledge about behavioural effects in this mouse model of impaired Nrg1 function and suggest that a number of the behavioural tests with relevance to schizophrenia are normal in these mice.
Introduction
One of the strongest candidate genes for schizophrenia reported so far is the neuregulin-1 gene (NRG1) (Harrison & Law, 2006 ; Stefansson et al. 2002 ; Tosato et al. 2005) . The neuregulins are a family of four genes encoding proteins that contain an epidermal growth factor (EGF)-like domain and signal through ErbB tyrosine kinases. More than 30 distinct isoforms of the single NRG1 gene are formed by extensive alternative splicing and multiple promoters (Mei & Xiong, 2008) . The isoform variants most commonly expressed in the brain contain a C-terminal transmembrane domain with a b-type EGF-like domain (Falls, 2006 ; Harrison & Law, 2006 ; Walss-Bass et al. 2006) . NRG1 gene expression has been detected in many brain regions, including schizophrenia-relevant areas such as the prefrontal cortex, hippocampus, cerebellum and substantia nigra. NRG1 is involved in neurodevelopment and synaptic plasticity, as well as regulation of neurotransmitter receptor expression and activation (Harrison & Law, 2006 ; O'Tuathaigh et al. 2007b ; Tosato et al. 2005) . Alterations in the expression of NRG1 mRNA have been found in the dorsolateral prefrontal cortex and hippocampus of patients with schizophrenia (Corfas et al. 2004 ; Harrison & Law, 2006) . However, there is no clear evidence for downregulation of NRG1 mRNA in schizophrenia and in fact some studies have shown up-regulation of certain NRG1 isoform ratios (Hashimoto et al. 2004 ; Law et al. 2006) .
Several Nrg1 mutant mouse lines have been developed (Duffy et al. 2008 ; O'Tuathaigh et al. 2007b ). Nrg1 transmembrane-domain heterozygous mutant (Nrg1 +/x ) mice (Stefansson et al. 2002) were reported to display hyperactivity when exposed to a novel environment, moderate deficits in prepulse inhibition (PPI), a model of sensory gating, and subtle changes in anxiety-like and socal behaviours (Karl et al. 2007 ; O'Tuathaigh et al. 2008) . The mice were also hypersensitive to the behavioural effects of cannabinoids (Boucher et al. 2007 ). However, so far only one study has addressed the pharmacological regulation of behaviour in these mice using behavioural tests with relevance to schizophrenia. The aim of the present study was therefore to investigate the effect of the dopamine releaser, amphetamine, and the NMDA glutamate receptor antagonists, phencyclidine (PCP) and MK-801, on locomotor activity in Nrg1 hypomorphic mutant mice. Psychotropic drug-induced locomotor hyperactivity has widely been used as an animal model of psychosis (Geyer & Markou, 1995 ; Van den Buuse et al. 2005 a) . Furthermore, we assessed the action of amphetamine and MK-801, the dopamine receptor agonist, apomorphine, and the 5-HT 1A receptor agonist, 8-hydroxy-dipropylaminotetralin (8-OH-DPAT), on PPI of startle. Drug-induced deficits in PPI are widely used as a model of sensorimotor gating deficits seen in schizophrenia and other psychiatric illnesses (Braff et al. 2007 ; Van den Buuse et al. 2005a) . To confirm and replicate previous studies, we also performed a detailed analysis of baseline locomotor activity in these mice using two different age cohorts and two different apparatus. Finally, given the putative central role of dopamine and serotonin neurotransmission in schizophrenia, we used receptor autoradiography to assess dopamine D 2 receptor binding density in the forebrain of these mice and, for comparison and because of PPI results in the study, the density of 5-HT 1A receptors.
Methods

Animals
The animals were bred and genotyped at the Garvan Institute, Sydney, Australia (Karl et al. 2007 ) and shipped to the Mental Health Research Institute animal facility where they were kept under standard conditions for at least 2 wk prior to behavioural testing. The animals were aged 12-16 wk at the time of behavioural testing except where indicated otherwise. Initially four cohorts of male mice were tested (Table 1) . Because the experiments with psychotropic drug-induced locomotor hyperactivity showed trends for differential effects between wild-type and Nrg1
mice, an additional cohort was used for a doseresponse study on the effect of MK-801 (Table 1) . Three weeks later, some of these mice were used for an amphetamine dose-response study (data not shown). All procedures were approved by the Animal Experimentation Ethics Committee of the University of Melbourne, Australia.
Open-field locomotor activity testing
Mice were placed individually in plastic boxes (39 lr 28 wr12 h cm) with sawdust on the floor and which were covered with a glass plate to prevent the animals from escaping. For a total duration of 180 min the animals were allowed to explore and habituate to the new environment. After 60 min the mice received a saline injection as part of preliminary drug hyperactivity experiments (data not shown). Mice were tested either at age 12-16 wk (first cohort) or at age 7-8 months (second cohort). Distance moved was analysed from video recordings using the Ethovision tracking system (Noldus, The Netherlands).
Photocell locomotor activity testing
Baseline locomotor activity and psychoactive druginduced locomotor hyperactivity were assessed using the TruScan Photobeam Activity system (Coulbourn Instruments, San Diego, USA). This system consists of a mouse enclosure (25.4r25.4r40.6 cm) surrounded by a sensor-ring which included a 16r16 array of photobeams and a computerized data-acquisition system. After 60 min of baseline locomotor activity and habituation to the test environment, the mice were injected and activity was monitored over a subsequent 120 min. From the various drug experiments, data obtained during the 60-min pre-injection period were pooled for analysis of baseline locomotor activity.
PPI testing
Startle, startle habituation and PPI of startle were assessed using an eight-unit automated system (SR-LAB, San Diego Instruments, USA). The mice were placed in clear Plexiglas cylinders which were closed on either side and acoustic stimuli were delivered over 70-dB background noise through a speaker in the ceiling of the box. Each testing session consisted of 104 trials with an inter-trial interval between 10 and 25 s. The first and last eight trials consisted of single 40-ms 115 -dB pulsealone startle stimuli. The middle 88 trials consisted of random delivery of 16 115-dB pulse-alone stimuli, eight trials during which no stimulus was delivered, and 64 prepulse trials. The total of 32 115-dB pulsealone trials was expressed as four blocks of eight and used to determine startle habituation. Prepulse trials consisted of a single 115-dB pulse preceded [by either a 30-ms or a 100-ms inter-stimulus interval (ISI)] by a 20-ms non-startling stimulus of 2, 4, 8 or 16 dB over the 70-dB baseline. Whole-body startle responses were converted into quantitative values by a piezo-electric accelerometer unit attached beneath the platform. Percentage prepulse inhibition ( %PPI) was calculated as pulse-alone startle response x prepulse+ pulse startle response pulse-alone startle response r100:
Drug treatments
All drugs were obtained from Sigma (USA) or Tocris (UK) and dissolved and diluted in 0.9 % saline. Mice were injected intraperitoneally (i.p.) with a 10 ml/kg volume using a 30-gauge needle. Doses were obtained from the literature (Geyer et al. 2001 (Geyer et al. , 2002 Gogos et al. 2008 ; Van den Buuse et al. 2005b, c) and from preliminary experiments. Mice received treatments in a pseudo-randomized, within-animal design with 3-4 d between experiments.
Receptor autoradiography
Sections (20 mm) of the nucleus accumbens, hippocampus or raphe region (Franklin & Paxinos, 1996) were cut on a cryostat and thaw-mounted onto gelatin-coated slides. Dopamine and 5-HT 1A receptor autoradiography were performed as previously described (Choy et al. 2009 ; Gogos et al. 2006 ) with slight modifications. Briefly, for dopamine D 2 receptor autoradiography, the total binding solution contained 1 nm of [ 3 H]YM-09151-2 (PerkinElmer Life Sciences, USA) with 0.1 mM pindolol and 0.5 mM DTG (1,3-di-o-tolylguanidine) added to mask 5-HT 1A and s receptors, respectively. For 5-HT 1A receptor autoradiography, the total binding solution contained 1 nm of [
3 H]8-OH-DPAT (Amersham Biosciences, UK). The non-specific binding solutions contained the same ligands except for the addition of 10 mM (x)-sulpiride or 1 mM serotonin (all Sigma-Aldrich), respectively. The sections and [
3 H] standard microscales (Amersham Biosciences) were apposed to an imaging plate (BAS-TR2025, Fuji, Japan) and analysed using Analytical Imaging Station software (Imaging Research, Canada). Receptor density was calculated by subtracting nonspecific binding values from total binding values, and converted to fmol/mg estimated tissue equivalent (ETE) using a standard curve and specific activity of the ligands. 
Data analysis
All data are expressed as mean ¡ standard error of the mean (S.E.M.). Genotypes were compared using two-way analysis of variance (ANOVA) with repeated measures where appropriate (Systat, version 9.0, SPSS software ; SPSS Inc., USA). In the ANOVA, the between-group factor was genotype and the withingroup, repeated-measures factors were treatment (drug vs. saline treatment), time (locomotor activity), prepulse intensity and startle block (PPI experiments). Differences were considered significant when p<0.05. Locomotor activity : effect of amphetamine, PCP and MK-801
Results
Baseline locomotor activity
After injection of saline, Nrg1 +/x mice aged 12-16 wk maintained their modest hyperactivity in the photocell cages [main effect : F(1, 39)=4.5, p=0.041 ; Fig. 2 ]. As expected, amphetamine treatment induced a rapid, prolonged and significant locomotor hyperactivity compared to saline treatment [main effect : F(1, 13)= 47.0, p<0.001 ; amphetaminertime interaction : F(23, 299)=8.9, p<0.001]. However, there was no genotype main effect or interaction, indicating that Nrg1 +/x mice responded similarly to amphetamine treatment compared to controls (Fig. 2) . Similarly to amphetamine, treatment with PCP rapidly induced significant locomotor hyperactivity [main effect : F(1, 39)=103.7, p<0.001 ; PCPrtime interaction : F(23, 897)=51.4, p<0.001 ; Fig. 2] . Other than the modest baseline hyperactivity in Nrg1 +/x mice compared to wild-type controls [main effect of genotype : F(1, 39)=4.9, p=0.033], there was no interaction of genotype with any of the other factors, indicating that the effect of PCP was similar in Nrg1 +/x mice and wild-type controls (Fig. 2) .
Treatment with MK-801 also induced significant locomotor hyperactivity [main effect : F(1, 23)=93.4, p<0.001 ; MK-801rtime interaction : F(23, 529)=53.8, p<0.001 ; Fig. 2 ]. There was a main effect of genotype [F(1, 23)=8.1, p=0.009] again reflecting the baseline hyperactivity in Nrg1
+/x mice compared to wild-type controls (Fig. 2) . There was no interaction of genotype with the effect of MK-801, suggesting its effect was similar in Nrg1 +/x mice and wild-type controls (Fig. 2) . In a separate cohort of mice, treatment with three different doses of MK-801 again caused significant locomotor hyperactivity [main effect of MK-801 dose : F(3, 63)=118.9, p<0.001 ; dosertime interaction : F(69, 1449)=14.8, p<0.001 ; Fig. 3 (Fig. 3) . Three weeks after completion of the MK-801 doseresponse experiment, some of these mice (n=8 for each genotype) were used again to assess the effect of 1 and 5 mg/kg amphetamine. As in the previous cohort (see Fig. 2 ), no significant differences were observed between Nrg1
+/x mice and wild-type controls at either dose (data not shown).
Baseline startle and PPI
There was no difference between Nrg1 +/x mice and wild-type controls in terms of startle amplitude (Fig. 4 +/x mice and wild-type controls at either ISI (Fig. 4) .
Drug-induced disruption of PPI : apomorphine, amphetamine, MK-801 and 8-OH-DPAT
Treatment with 5 mg/kg apomorphine disrupted PPI at the 100-ms ISI [F(1, 19)=17.3, p=0.001] but not the 30-ms ISI. Apomorphine treatment had no effect on startle amplitude (Fig. 4) 
or its habituation (data not shown). There was no difference between Nrg1
+/x mice and wild-type controls in the effect of apomorphine (Fig. 4) . Treatment with 5 mg/kg amphetamine disrupted PPI at both 30-ms and 100-ms ISI [F(1, 19)=12.5 and 35.2, p=0.002 and p<0.001, respectively]. Although there was a trend for the disruption of PPI at the 30-ms ISI to be greater in Nrg1
+/x mice than in wild-type controls (Fig. 4) , this effect was not reflected in a significant genotyperdrug interaction. Furthermore, amphetamine treatment had no effect on startle amplitude (Fig. 4) mice (p=0.019) but was not significantly altered in wild-type controls (Fig. 4) . However, treatment with 8-OH-DPAT also markedly reduced startle amplitude [F(1, 19)=8.4, p=0.009], suggesting sedative effects (Fig. 4) . Inspection of the data (Fig. 4) suggests that this effect was particularly pronounced in Nrg1 +/x mice although there was no significant genotyperdrug interaction on startle amplitude. A possible interaction of the effect of 8-OH-DPAT on PPI with its effect on startle was also suggested by additional analysis of covariance (ANCOVA) which showed that, if startle amplitudes before and after 8-OH-DPAT were included as covariates, the 8-OH-DPATrgenotype interaction was no longer significant.
Dopamine D 2 receptors and 5-HT 1A receptors
Autoradiographic analysis of the density of dopamine D 2 receptors in the nucleus accumbens and caudate nucleus and 5-HT 1A receptors in the hippocampus and raphe nuclei revealed no differences between Nrg1
+/x mice and controls (Fig. 5) .
Discussion
Nrg1
+/x mice showed a modest spontaneous locomotor hyperactivity at age 12-16 wk in two different experimental conditions. Despite this spontaneous hyperlocomotion, the effect of the psychostimulant drugs, amphetamine, PCP and MK-801 was not significantly different between the genotypes. In addition, there were no differences between Nrg1
+/x mice and wild-type controls in PPI or its disruption by treatment with apomorphine, amphetamine and MK-801. Treatment with 8-OH-DPAT disrupted PPI in Nrg1 +/x mice but not in controls ; however, this treatment also induced a marked reduction of startle amplitude which may have influenced the PPI result. These results add to the growing knowledge on behavioural changes (or lack thereof) in these transmembrane Nrg1 +/x mice (Boucher et al. 2007 ; Karl et al. 2007 ; O'Tuathaigh et al. 2006 O'Tuathaigh et al. , 2007a O'Tuathaigh et al. , 2008 . As outlined in the Introduction, NRG1 has been identified as a candidate gene for schizophrenia and the expectation could, therefore, be that Nrg1 +/x mice display behavioural changes in psychotropic drug-induced locomotor hyperactivity and PPI deficits. However, the present results show a mainly wild-type-like response of transmembrane Nrg1 +/x mice.
Spontaneous hyperlocomotion has been observed in Nrg1
+/x mice by a number of previous studies (Boucher et al. 2007 ; Karl et al. 2007 ; O'Tuathaigh et al. 2006 O'Tuathaigh et al. , 2007a O'Tuathaigh et al. , 2008 and was replicated here in two different experimental protocols. The extent of this baseline hyperactivity was modest and there was no change in the level of habituation to the new environment. In one cohort, tested at age 7-8 months, no hyperactivity was observed. This finding is in contrast to previous studies by Karl and co-workers who suggested a more pronounced hyperactivity in Nrg1
mice aged 4-6 months compared to those aged 3-4 months (Karl et al. 2007 ). However, that study also suggested that the relative locomotor hyperactivity in Nrg1 +/x mice was sensitive to housing conditions (Karl et al. 2007) . It is therefore possible that differences between the housing, husbandry and handling procedures between the laboratories influenced the results, as has been shown for other mutant mouse models (Bailey et al. 2006) . Furthermore, differences in the test conditions, such as the size of the open field used or lighting conditions cannot be excluded as contributing to the observed variations. Spontaneous hyperlocomotion is often rather simplistically considered an indication of enhanced dopaminergic activity in the basal forebrain and, as such, a model of the postulated hyperdopaminergia in schizophrenia. This correlation is only partially correct, as enhanced locomotor activity can be induced by a wide range of central neurotransmitter changes, such as those induced by NMDA receptor antagonists, serotonin re-uptake inhibitors and noradrenergic drugs, either directly or via modulation of dopaminergic activity (e.g. Britton et al. 1984 ; Brocco et al. 2002 ; Chartoff et al. 2005 ; Juhila et al. 2005) . The moderate locomotor hyperactivity in Nrg1 +/x mice could Left-hand panels show representative autoradiograms of (a) total D 2 receptor binding in the forebrain, (b) 5-HT 1A receptor binding in the hippocampus, and (c) raphe region in wild-type controls. Right-hand panels show group data for (d) D 2 receptors in the nucleus accumbens core (NAcC) and shell (NAcS) regions and the caudate nucleus (CN) and (e) for 5-HT 1A receptors in the CA1 and dentate gyrus (DG) regions of the hippocampus, the dorsal raphe nucleus (DRN) and median raphe nucleus (MRN). There were regional differences in binding density but no differences between Nrg1 +/x mice and wild-type controls. (Dean et al. 2008) . The latter finding would be in line with the observed lack of difference between the genotypes in the effect of treatment with PCP or MK-801 on locomotor activity or PPI.
Baseline PPI was not different between Nrg1
+/x mice and controls. This result is in contrast to the small decrease of baseline PPI observed in these mice in one study (Stefansson et al. 2002) , but confirms the lack of a genotype difference in another study (Boucher et al. 2007) . A notable exception to the relative lack of differences between Nrg1 +/x mice and wild-type controls was in the effect of 8-OH-DPAT on PPI. Interestingly, several previous studies (Geyer et al. 2002) and our own work (Gogos et al. 2008) have shown that the predominant response to 8-OH-DPAT is to have no effect or enhance PPI in mice, as opposed to the disruption more commonly seen in rats (Gogos et al. 2008) . While the wild-type controls showed the expected lack of effect of 8-OH-DPAT, it was therefore surprising to observe a decrease of PPI in Nrg1
mice. However, this result has to be interpreted with caution as these mice also displayed a marked fall in startle amplitude which was numerically greater than in wild-type controls. While PPI is calculated as a percentage of startle amplitude, it should theoretically be independent of the level of startle. However, it has become clear that there is no such straightforward relationship (see Csomor et al. 2008 and references therein) . Therefore, further analysis is needed to determine if 8-OH-DPAT treatment can differentially affect PPI in Nrg1 +/x mice and wild-type controls in the absence of sedation or differential effects on startle. We observed no differences in the density of 5-HT 1A receptors between Nrg1 +/x mice and wild-type controls which would be in line with the lack of a specific difference in the effect of 8-OH-DPAT on PPI. There is limited information on similar experimental results in other mutant models with directly or indirectly modified Nrg1 production and, in particular, psychotropic drug-induced hyperlocomotion has been little studied. Mice heterozygous for a mutation in the Nrg1 immunoglobulin-like domain were not hyperactive but displayed disrupted latent inhibition, another sensory gating mechanism (Rimer et al. 2005) . Mice heterozygous for Heregulin (type I Nrg1) were hyperactive in the open field but no sensory gating mechanisms were studied (Gerlai et al. 2000) . Mice heterozygous for the type III Nrg1 isoform were not hyperactive in the open field but showed disrupted PPI (Chen et al. 2008) . Beta-site APP-cleaving enzyme 1 (BACE1) is involved in the metabolism of Nrg1. BACE1 knockout mice showed baseline locomotor hyperactivity and disrupted PPI, and were hypersensitive to the effect of MK-801 (Savonenko et al. 2008 ). Brain-specific conditional knockouts of erbB4 (Golub et al. 2004 ), a Nrg1 receptor, and mice in which erbB4 signalling was blocked in oligodendrocytes (Roy et al. 2007) showed reduced spontaneous locomotor activity in the home cage and enhanced responding to amphetamine. On the other hand, erbB4 hypomorphs were reported to be hyperactive (Stefansson et al. 2002) . Taken together, these studies show a variety of behavioural phenotypes resulting from genetic modification of Nrg1 function. While these differences between studies could reflect the wide spectrum of involvement of Nrg1 in behavioural regulation, methodological differences between the studies cannot be excluded. Comparison of the above studies reveals a wide range of behavioural assays and end-points, the review of which is beyond the scope of this paper. Importantly, little work has been done to identify the neurotransmitter substrates for the reported behavioural changes, e.g. by using pharmacological challenges, as was done in the present study.
In conclusion, we investigated the behaviour of Nrg1 +/x mice in a number of behavioural animal models of aspects of schizophrenia. While there was a modest increase in spontaneous locomotor activity, there were no specific differences in psychotropic drug-induced locomotor hyperactivity, PPI and its regulation, or in dopamine D 2 receptor levels in the forebrain. The data do not negate the importance of NRG1 as a candidate gene for schizophrenia but suggest that the transmembrane Nrg1 mutation does not induce marked functional changes in the behavioural domain of psychotropic drug-induced locomotor hyperactivity and disruption of PPI.
